Cell & Gene: The Podcast Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rahkit
10 snips
Dec 5, 2024 Dr. Amit Rhakit is the Chief Medical Officer at BlueRock Therapeutics, where he focuses on cutting-edge cell therapies for Parkinson's disease. He delves into how their therapy, bemdaneprocel, restores dopamine-producing neurons, contrasting it with conventional treatments. The discussion highlights the significant benefits these advancements could have on patient quality of life. Rhakit also shares insights on the personal stories of those living with Parkinson's, emphasizing the transformative potential of innovative therapies in managing symptoms.
AI Snips
Chapters
Transcript
Episode notes
Limitations of Current PD Medications
- Current Parkinson's medications, primarily dopamine replacements, lose effectiveness over time, about five years.
- This necessitates more frequent doses or stronger medications, leading to limitations and the need for alternative therapies.
BlueRock's Cell Therapy Approach
- BlueRock's bemdaneprocel is a cell therapy using stem cells to create dopamine-producing neurons implanted in the brain.
- This approach aims to restore the neural network, potentially improving motor and non-motor functions not addressed by dopamine replacement.
Personal Connection to Parkinson's
- Amit Rhakit shares a personal story of a friend in Paris diagnosed with Parkinson's.
- He witnessed his friend's progressive decline over five years, highlighting the impact of the disease on daily life and the need for better treatments.